WealthPLAN Partners LLC Has $1.31 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

WealthPLAN Partners LLC reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 33.2% during the first quarter, Holdings Channel reports. The institutional investor owned 2,657 shares of the medical research company’s stock after selling 1,319 shares during the period. WealthPLAN Partners LLC’s holdings in Thermo Fisher Scientific were worth $1,306,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Evergreen Private Wealth LLC lifted its stake in shares of Thermo Fisher Scientific by 1.8% in the first quarter. Evergreen Private Wealth LLC now owns 13,450 shares of the medical research company’s stock valued at $6,611,000 after buying an additional 235 shares in the last quarter. Resonant Capital Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 10.6% in the 1st quarter. Resonant Capital Advisors LLC now owns 2,146 shares of the medical research company’s stock worth $1,056,000 after acquiring an additional 205 shares during the last quarter. Unified Investment Management lifted its position in Thermo Fisher Scientific by 7.0% in the 1st quarter. Unified Investment Management now owns 1,144 shares of the medical research company’s stock valued at $562,000 after acquiring an additional 75 shares in the last quarter. Cohen Investment Advisors LLC boosted its stake in Thermo Fisher Scientific by 1.0% during the 1st quarter. Cohen Investment Advisors LLC now owns 7,175 shares of the medical research company’s stock valued at $3,527,000 after purchasing an additional 69 shares during the last quarter. Finally, Integrated Advisors Network LLC lifted its holdings in shares of Thermo Fisher Scientific by 2.4% in the first quarter. Integrated Advisors Network LLC now owns 2,222 shares of the medical research company’s stock valued at $1,092,000 after purchasing an additional 52 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.3%

NYSE:TMO opened at $515.92 on Wednesday. Thermo Fisher Scientific Inc. has a 12 month low of $403.36 and a 12 month high of $643.99. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The firm’s 50 day moving average is $475.12 and its 200 day moving average is $517.04. The stock has a market capitalization of $191.73 billion, a PE ratio of 28.36, a price-to-earnings-growth ratio of 2.29 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. During the same period in the prior year, the firm earned $5.15 earnings per share. The company’s revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s payout ratio is 10.34%.

Insider Activity at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on TMO. DZ Bank started coverage on Thermo Fisher Scientific in a research report on Friday, March 27th. They issued a “buy” rating and a $610.00 price target for the company. Sanford C. Bernstein began coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 target price for the company. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target on the stock. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a report on Monday. Finally, Piper Sandler started coverage on Thermo Fisher Scientific in a research report on Thursday, June 11th. They set a “neutral” rating and a $510.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $601.61.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.